Keio University

III 期 CREST 研究结果显示，与单独使用标准治疗相比，Sasanlimab 联合卡介苗（BCG）膀胱灌注治疗，可使疾病相关事件（包括高级别疾病复发或进展等）风险降低 32%皮下注射 PD-1 抑制剂Sasanlimab联合卡介苗治疗既往未接受过卡介苗治疗的高危非肌层浸润性膀胱癌患者，有望成为 30 余年来该治疗领域的首个突破性进展相关研究结果已提交至全球卫生监管机构，以支持潜在的注册申报辉瑞公司4月26日宣布，针对其在研创新药Sasanlimab的关键性III期CREST临床试验达到主要研究终点。Sasanlimab是一款皮下注射PD-1单抗（mAb），该研究旨在评估Sasanlimab联合标准治疗（SOC）卡介苗（BCG）诱导伴或不伴维持治疗，在既往未接受过卡介苗治疗的高危非肌层浸润性膀胱癌（NMIBC）患者中的疗效，试验已达到主要终点，即研究者评估的无事件生存期（EFS）。与单独使用卡介苗（诱导伴维持）治疗相比，Sasanlimab与卡介苗（诱导伴维持）的联合治疗方案显示出具有临床意义且统计学显著的无事件生存期（EFS）改善：风险比(HR)为0.68; 95%置信区间（CI），0.49-0.94；双臂p值=0.019；中位无事件生存期（mEFS）尚未达到。研究显示，相比对照组，联合治疗方案可将疾病相关事件（包括高级别疾病复发或进展）风险降低32%。在预设的更高风险患者亚组中，联合治疗组在无事件生存期方面均展现出一致的获益，其中T1期患者的无事件生存期风险比（HR）为0.63 (0.41, 0.96) ，伴有原位癌（CIS）的患者无事件生存期风险比（HR）为0.53 (0.29, 0.98)。无事件生存期（EFS）是一个复合终点，指从随机分组到首次出现高级别疾病复发、疾病进展、原位癌持续存在或因任何原因导致的死亡等事件的时间。在接受 Sasanlimab 联合卡介苗（诱导伴维持）治疗的患者中，在第36 个月时无事件生存率为 82.1%（95% CI, 77.4-85.9）；而在仅接受卡介苗（诱导伴维持）治疗的患者中，这一比例为 74.8% (95% CI, 69.7-79.2)。CREST 研究结果已于4月26日-29日举行的 2025 年美国泌尿外科协会（AUA）年会期间，在全体大会口头报告环节公布。“长期以来，膀胱癌的临床治疗亟需能够降低疾病复发和进展风险的创新方案。几十年来，卡介苗膀胱灌注免疫治疗都是肿块切除术后的标准治疗方案，但仍有高达50%的高危非肌层浸润性膀胱癌（NMIBC）患者治疗失败。”卡罗莱纳泌尿外科研究中心医学主任、CREST试验主要研究者、美国外科医师学会(FACS)会员Neal Shore博士表示，"CREST III期研究结果表明，在疾病早期阶段将Sasanlimab联合卡介苗（诱导伴维持）作为治疗方案，能够显著延长患者的无事件生存期，显示出联合治疗方案在重塑膀胱癌临床治疗格局、减轻患者疾病负担方面的潜力与价值。"膀胱癌是全球第九大癌症，每年约造成22 万人死亡1,2。其中，非肌层浸润性膀胱癌约占所有膀胱癌的 75%3。尽管卡介苗治疗已证实可降低肿瘤复发风险，但是40%-50%的高危非肌层浸润性膀胱癌患者在接受这一治疗后，仍会出现疾病复发或进展4-6。“最新的关键性 III 期 CREST 试验结果为膀胱癌患者带来了期待已久的治疗突破。作为三十多年来首个与卡介苗联用的免疫治疗，Sasanlimab能为既往未接受过卡介苗治疗的高危非肌层浸润性膀胱癌患者带来显著获益。” 辉瑞肿瘤事业部首席开发官 、Megan O’Meara博士表示，“CREST的研究结果对早期膀胱癌患者意义重大，皮下注射的免疫检查点抑制剂能有效延缓疾病复发或进展，帮助这类患者从创新治疗方案中得到更多生存获益。这些研究结果也进一步彰显了辉瑞对处于不同疾病进展阶段的膀胱癌患者的长期承诺。我们期待与全球监管机构合作，让Sasanlimab成为高危非肌层浸润性膀胱癌的重要治疗选择。”在关键次要终点分析中，与单独使用卡介苗诱导伴维持治疗相比，Sasanlimab 联合卡介苗（仅诱导）治疗，未能延长无事件生存期（EFS）：风险比(HR)为1.16；95%置信区间（CI），0.87-1.55；双臂p值=0.312。这一结果显示，卡介苗维持治疗不仅是标准治疗方案的一部分，也是联合Sasanlimab治疗的关键组成部分。针对另一关键次要终点总生存期（OS），较早的中期分析显示，在中位随访40.9个月时，各治疗组之间尚未观察到差异。该研究将继续进行生存随访，并在最终分析中对OS进行评估。对于在随机分组时伴有原位癌的患者，完全缓解率（CR）及其持续缓解时间是研究设定的额外次要终点。分析结果显示，Sasanlimab联合卡介苗诱导伴维持治疗组与单独使用卡介苗诱导伴维持治疗组在任何时间点达到的完全缓解率分别为89.8%和 85.2 %。值得注意的是，对于在随机分组时伴有原位癌的患者中，在第36个月时，Sasanlimab联合治疗组中仍然有91.7%保持完全缓解，而在单独使用卡介苗治疗组中，这一数字为67.7%。Sasanlimab联合卡介苗治疗的总体安全性表现与已知的卡介苗安全性表现以及Sasanlimab在临床试验中报告的数据一致。Sasanlimab的安全性表现也与已公布的PD-1抑制剂安全性表现相一致。辉瑞已将相关数据提交至全球卫生监管机构，以支持潜在的注册申报。关于CREST滑动阅览CREST 试验是一项 III期、国际多中心、随机、开放性、三个平行组研究，旨在评估PD-1 单抗Sasanlimab联合卡介苗（BCG）（BCG诱导伴或不伴维持）治疗，与单独使用卡介苗（BCG）（诱导伴维持）治疗相比，在既往未接受卡介苗（BCG）治疗的高危非肌层浸润性膀胱癌（NMIBC）患者中的疗效。患者被随机分配接受以下几种治疗：每四周皮下（SC）注射一次 300毫克Sasanlimab，最多注射 25 个周期（一个周期为四周），同时联合卡介苗每周一次连续六周（诱导期），之后进行（A 组；n=352）或不进行（B 组，n=352）卡介苗（BCG）维持治疗；或者仅接受卡介苗（BCG）诱导伴维持治疗直至 25 个周期（C 组，n=351）。主要终点是由研究者评估的 A 组和 C 组之间的无事件生存期（EFS），作为复合终点定义为从随机分组到首次出现高级别疾病复发、疾病进展、原位癌（CIS）持续存在、任何原因导致的死亡任一事件的时间。关键次要终点包括由研究者评估的 B 组和 C 组之间的无事件生存期（EFS），A/B 组与 C 组之间的 OS。在伴有原位癌（CIS）的患者中，完全缓解率（CR）及其持续时间是额外次要终点。有关 CREST 试验的更多信息（NCT04165317），请访问 www.clinicaltrials.gov。关于 Sasanlimab滑动阅览Sasanlimab是一种人源化免疫球蛋白G4（IgG4）单克隆抗体，通过与人PD- 1受体的高亲和力结合，阻断与 PD-1 和 PD-L1/PD-L2 的相互作用。PD-1 是一种在 T 细胞、树突状细胞、自然杀伤细胞、巨噬细胞和 B 细胞上表达的蛋白质，作为免疫检查点，当其配体激活时，能够负向调节 T 细胞的激活和效应功能，并可能在肿瘤逃逸宿主免疫过程中发挥重要作用。Sasanlimab 可以通过每四周一次的皮下注射（2 毫升）给药。在早期临床研究中，每四周皮下注射 300 毫克的 Sasanlimab 在晚期实体瘤和晚期尿路上皮癌中显示出临床疗效。除了用于非肌层浸润性膀胱癌（NMIBC），Sasanlimab与辉瑞的抗体偶联物（ADC）的联合疗法也正在进行多项临床研究。关于辉瑞肿瘤滑动阅览在辉瑞肿瘤，我们身处癌症治疗新纪元的最前沿。我们拥有行业领先的产品组合和广泛的产品管线，聚焦小分子药物、抗体偶联药物（ADC）、双特异性抗体等免疫疗法三个核心作用机制、从多个方向着手攻克癌症。我们致力于为乳腺癌、泌尿系统肿瘤、血液肿瘤、消化道肿瘤、妇科肿瘤和包括肺癌在内的胸部肿瘤等全球高发癌种提供变革性的治疗方案。在科学的驱动下，辉瑞致力于加快突破性创新的步伐，帮助肿瘤患者延长生命、改善生活质量。关于辉瑞：为患者带来改变其生活的突破创新滑动阅览在辉瑞，我们通过科学和全球资源为人们提供治疗方案，以延长其生命，显著改善其生活。在医疗卫生产品的探索、研发和生产过程中，辉瑞始终致力于奉行严格的质量、安全和价值标准。我们在全球的产品组合包括创新药品和疫苗。每天，辉瑞在发达和新兴市场的员工都在推进人类健康，推动疾病的预防、治疗和治愈，以应对挑战我们这个时代的顽疾。辉瑞还与医疗卫生服务方、政府和社区合作，支持并促进世界各地的人们能够获得更为可靠和可承付的医疗卫生服务。这与辉瑞作为一家全球卓越的创新生物制药公司的责任是一致的。175年来，辉瑞一直致力于为所有依赖我们的人带来改变。如需了解更多信息，请登录www.pfizer.com.cn。免责声明：本新闻稿仅在于传递科学前沿信息，不构成对任何药物或治疗方案的推荐或推广。如您有药物或治疗方面的问题，请咨询医疗卫生专业人士。滑动查看1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263.2. Bladder cancer statistics. World Cancer Research Fund International. Accessed March 20, 2025. https://www.wcrf.org/cancer-trends/bladder-cancer-statistics/ 3. Babjuk M, Bohle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–61.4. Gaul Frau J, Palou J, Rodriguez O, et al. Failure of Bacillus Calmette-Guerin therapy innon-muscle-invasive bladder cancer: definition and treatment options. Arch Esp Urol. 2016;69(7):423–33.5. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-477.6. Ritch CR, Velasquez MC, Kwon D, et al. Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort. J Urol. 2020;203(3):505-511.                                                                                            往期 · 推荐遏制耐药，拯救生命，我们在行动！生命的韧性：与多发性骨髓瘤共处辉瑞靶向免疫疗法易瑞欧®（埃纳妥单抗）在华获批，用于治疗复发或难治性多发性骨髓瘤【一键通达】药品问询不再难，医学信息解忧烦!

The most effective drug for Parkinsons disease hasnt changed in 50 years. But fresh research published in one of the countrys top scientific journals is helping build the case for a more cutting-edge approach that uses stem cells to restore important brain functions.The second most common neurodegenerative illness, Parkinsons, is caused by the loss of certain nerve cells. These cells produce a chemical messenger, dopamine, that plays a crucial role regulating movement. Since the 1970s, a drug called levodopa, which the body converts into dopamine, has been the mainstay treatment for combating the tremors, slowness, stiffness and balance issues that come with Parkinsons.Levodopa doesnt stop the disease, however, so scientists have spent decades trying to find a more permanent fix. The latest development in that search comes from two clinical trials testing stem cell-derived therapies transplanted into the brains of Parkinsons patients.The first of those trials, conducted at the Kyoto University Hospital in Japan, evaluated seven people who received what are essentially blank slate cells that can turn into dopamine-producing neurons. These cells were created using a technology pioneered at Kyoto University, where roughly 20 years ago, scientists discovered how to reset some adult human cells to act like stem cells.The studys main focus was safety. Results, published Wednesday in Nature, show no serious adverse events were reported, though researchers did identify 73 mild to moderate events. Importantly, there was no evidence the introduced cells started growing in an unchecked, tumor-like fashion a major concern with stem cell implants.The study also explored whether this therapy had any effect on patients disease. Two years post-treatment, the six participants who were evaluable had gotten better on a scale clinicians use to measure the severity of Parkinsons motor symptoms. Researchers looked at whats known as on time, when medications are adequately controlling these symptoms, as well as the opposite off time, and found scores improved an average of 36% and 20%, respectively.Another test indicated that dopamine-producing cell activity had increased substantially. This was determined through a technique in which researchers strap a radioactive element to a molecule of levodopa and then use a PET scan to follow its path through the nervous system, somewhat like how a submarine tracks objects on a sonar display.The second trial took place at sites throughout the U.S. and Canada, and employed a different kind of stem cell that comes from human embryos. It enrolled a total of 12 participants and followed them for a year post-transplant.Similar to the Japan study, there were no deaths, serious adverse events or tumor-like tissue growth related to the introduced cells. Trial runners did report two serious events overall. One participant was hospitalized with COVID-19, while another had a seizure that was attributed to the surgical procedure.The trial also saw improvements in off scores on that disease severity scale and positive results from the radioactive levodopa test.The cell therapy tested, called bemdaneprocel, is being developed by Bayer subsidiary BlueRock Therapeutics, which back in August 2023 announced some of the data published Tuesday. The company expects to start a Phase 3 trial before the end of June.Hideyuki Okano, a stem-cell scientist at Keio University in Tokyo, argues more research is needed to confirm these types of cell therapies are effective against Parkinsons.Still, in an accompanying Nature editorial, he called the new trial results encouraging because they suggest treating Parkinsons patients with donor cell transplants is likely safe. That both trials proved to be safe, and hinted at possible efficacy, is an important step towards the establishment of this cell therapy for Parkinsons disease in wider society, he wrote.Cell therapy for Parkinsons isnt a new idea. In 1989, a team led by neuroscientist Olle Lindvall performed the first cell transplantations for Parkinsons patients. While the landmark study didnt show a major therapeutic benefit, a few interesting signals encouraged the research community to keep exploring.One ethical concern from that trial was that it used a relatively large amount of tissue derived from aborted fetuses. In the decades since, Parkinsons and cell biology experts have made significant progress identifying other, less controversial sources of stem cells that can be scaled more easily.A milestone of that work came in 2020, when the technique invented at Kyoto University was used to turn a Parkinsons patients own skin cells into the early stages of dopamine-producing neurons, which were then implanted into his brain.According to Okano, as of December, there were 115 clinical trials testing 83 products derived from pluripotent stem cells. And among those targeting central nervous system disorders, the ones for Parkinsons disease are at a more advanced stage of development.Further behind Bayer and BlueRock, Aspen Neuroscience, a San Diego-based biotechnology company, has a Parkinsons therapy derived from patients own cells currently in early-stage human testing. '

▎药明康德内容团队编辑本期看点1. Arvinas公司宣布，其靶向富含亮氨酸重复激酶2（LRRK2）的在研靶向蛋白降解剂ARV-102在首个人体临床试验中表现出良好的安全性和耐受性，并显著降低中枢神经系统和外周LRRK2水平，支持其在神经退行性疾病中的继续评估。2. 罗氏（Roche）新一代阿尔茨海默病疗法在1b/2a期临床试验中快速清除受试者大脑中的β淀粉样蛋白（Aβ），计划今年启动3期临床试验。药明康德内容团队整理Arvinas帕金森病蛋白降解疗法临床结果积极Arvinas公司公布了其在研靶向蛋白降解嵌合体（PROTAC）候选药物ARV-102的首次人体临床试验数据。ARV-102是一种针对富含亮氨酸重复激酶2（LRRK2）的蛋白降解剂。LRRK2是一种大型多结构域支架激酶。LRRK2活性和表达升高被认为与多种神经系统疾病的发病机制相关，包括LRRK2基因型和散发型帕金森病以及进行性核上性麻痹。试验的主要发现包括：ARV-102在单次或多次给药后总体安全性良好，未报告严重不良事件ARV-102在脑脊液（CSF）中的暴露呈剂量依赖性增加，表明其具有良好的穿越血脑屏障的能力单次口服剂量≥60 mg，或每日重复口服剂量≥20 mg时，CSF中LRRK2降解率超过50%，外周单核细胞中LRRK2降解率超过90%，表明ARV-102可实现中枢神经系统及外周LRRK2蛋白的显著降解单次给药后观察到外周单核细胞中磷酸化Rab10的显著减少，这是LRRK2下游活性的生物标志物除了在健康志愿者中进行的这项1期临床试验，Arvinas也已在帕金森病患者中启动了ARV-102的1期单剂量递增（SAD）临床试验给药。公司预计将在2025年完成该SAD队列的入组并公布初步数据，并将在帕金森病患者中启动多剂量递增队列的临床研究。该公司首席医学官Noah Berkowitz博士在新闻稿中表示，ARV-102能够穿越血脑屏障并降解LRRK2蛋白的能力，为治疗严重神经退行性疾病提供了潜在的颠覆性治疗策略。罗氏新一代阿尔茨海默病疗法快速清除β淀粉样蛋白罗氏日前公布了其新一代抗Aβ抗体trontinemab在1b/2a期临床试验Brainshuttle AD中的最新结果。初步数据显示，114名参与者接受trontinemab治疗后，经淀粉样蛋白正电子发射断层扫描（PET）测量，其脑内淀粉样蛋白斑块迅速且明显地呈剂量依赖性减少。28周后，在3.6 mg/kg剂量组中，81%的参与者（n=21/26）的淀粉样蛋白斑块几乎全部清除。根据该领域数据，降低淀粉样蛋白斑块的速度以及早期将其降至阳性阈值以下的能力，对于在早期阿尔茨海默病患者中实现具有临床意义的益处至关重要。Trontinemab是一款运用罗氏大脑穿梭（brain shuttle）技术的新一代抗淀粉样蛋白单克隆抗体。它将靶向淀粉样蛋白的单克隆抗体与可以和转铁蛋白受体相结合的蛋白域融合，可以有效协助抗体穿越血脑屏障，在用药3-6个月后可以快速有效地清除大脑中的淀粉样蛋白沉积。罗氏计划在今年晚些时候，启动trontinemab的3期临床试验。KER-065：公布1期临床试验初步顶线结果Keros Therapeutics日前公布了KER-065在健康志愿者中进行的1期临床试验的初步顶线结果。KER-065是一种激活素受体IIA（ActRIIA）和激活素受体IIB（ActRIIB）配体陷阱（ligand trap），被设计用于结合并抑制肌生长抑制蛋白和激活素A，从而促进骨骼肌再生、增加肌肉体积和力量、降低体脂、减少骨骼肌纤维化并增强骨骼强度。Keros Therapeutics正在开发KER-065用于治疗神经肌肉疾病，初步聚焦于杜氏肌营养不良症（DMD）。试验的主要发现包括：KER-065总体耐受性良好，未报告严重不良事件或剂量限制性毒性在各相关组织中均显示出对激活素抑制作用的证据，受试者身体成分发生改变，表现为骨密度和肌肉量增加、脂肪量减少，这些变化总体上与激活素信号通路被抑制一致CER-1236：IND申请获FDA许可CERo Therapeutics公司宣布，该公司为在研细胞疗法CER-1236递交的IND申请已获得美国FDA的许可，用于针对晚期实体瘤的1期临床试验，具体包括非小细胞肺癌和卵巢癌。新闻稿指出，CER-1236是首个以Tim-4L为靶点的CAR-T细胞疗法，也是首个通过改造T细胞，赋予其吞噬活性的疗法。临床前数据表明，这种双重机制可能有助于克服一直困扰实体瘤CAR-T细胞疗法的耐药障碍。RB-164：IND申请获FDA许可Radiance Biopharma日前宣布，该公司为在研抗体偶联药物（ADC）RB-164递交的IND申请已经获得美国FDA的许可。它是一种以ROR-1为靶点的ADC。该IND支持在美国启动RB-164的1期剂量递增及扩展临床试验，试验对象为ROR-1阳性的血液癌症及实体瘤患者。RB-164是一种新一代ADC，采用Fc静默单克隆抗体靶向ROR-1，并通过位点特异性偶联实现药物/抗体比例分布均一，从而改善药代动力学及毒理学特性，其药物载荷为MMAE。EPI-321：IND申请获FDA许可Epicrispr Biotechnologies宣布，在研疗法EPI-321的IND申请已获FDA的许可。EPI-321是一种潜在“first-in-class”的表观遗传学疗法，用于治疗面肩肱肌营养不良症（FSHD），这是一种遗传性神经肌肉疾病。该公司计划于2025年启动全球性1/2期临床试验。EPI-321是一种在研一次性基因调节疗法，旨在抑制DUX4的异常表达，DUX4是一种在FSHD中被错误激活并导致渐进性肌肉变性的基因。EPI-321通过临床验证的腺相关病毒（AAV）载体进行全身给药，在临床前模型中已证明它能有效抑制DUX4的表达并保护肌肉组织。EPI-321已获得FDA快速通道资格、罕见儿科疾病认定和孤儿药资格。DM-101PX：1期临床试验结果积极Desentum Oy公司日前宣布了在研桦树花粉过敏疫苗DM-101PX的积极1期临床数据。数据显示，DM-101PX的短程治疗在桦树花粉过敏患者中表现出良好的安全性和耐受性，并能诱导出非常强烈且持久的过敏原特异性IgG4应答。研究发现，DM-101PX诱导产生的免疫球蛋白能够有效阻断IgE介导的嗜碱性粒细胞激活，从而支持该产品有望诱导出保护性免疫应答。DM-101PX是一款用于免疫治疗桦树花粉过敏的在研疗法，其活性成分是主要桦树花粉过敏原Bet v 1的重组变体，通过基因工程改造降低了其致敏性，同时保留了所需的免疫学特性。▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料（可上下滑动查看）[1] CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors. Retrieved March 31, 2025, from https://www.globenewswire.com/news-release/2025/03/31/3052257/0/en/CERo-Therapeutics-Holdings-Inc-Receives-FDA-Clearance-of-Second-Investigational-New-Drug-Application-to-Initiate-Phase-1-Clinical-Trial-of-Lead-Compound-CER-1236-in-Solid-Tumors.html[2] Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers. Retrieved March 31, 2025, from https://www.globenewswire.com/news-release/2025/03/31/3052085/0/en/Keros-Therapeutics-Announces-Initial-Topline-Results-from-the-Phase-1-Clinical-Trial-of-KER-065-in-Healthy-Volunteers.html[3] Radiance Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of RB-164™, an ROR-1 Targeted ADC, for Hematologic and Solid Malignancies. Retrieved March 31, 2025, from https://www.globenewswire.com/news-release/2025/03/31/3052547/0/en/Radiance-Announces-FDA-Clearance-of-IND-Application-for-a-Phase-1-Clinical-Trial-of-RB-164-an-ROR-1-Targeted-ADC-for-Hematologic-and-Solid-Malignancies.html[4] Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD. Retrieved April 5, 2025, from  https://epicrispr.com/epicrispr-biotechnologies-announces-fda-clearance-of-ind-application-for-epi-321-a-first-in-class-epigenetic-therapy-for-fshd/[5] Desentum reports strong safety and immunological data from Phase 1 clinical study with investigational birch pollen allergy vaccine DM-101PX. Retrieved April 5, 2025, from https://desentum.fi/news/desentum-reports-strong-safety-and-immunological-data-from-phase-1-clinical-study-with-investigational-birch-pollen-allergy-vaccine-dm-101px/[6] Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors. Retrieved April 5, 2025, from https://www.businesswire.com/news/home/20250403585991/en/Vividion-Therapeutics-Doses-First-Patient-in-Phase-I-Study-of-RAS-PI3K-Inhibitor-for-Treatment-of-Advanced-Solid-Tumors[7] Pretzel Therapeutics Initiates Phase 1 Clinical Study Evaluating PX578, Lead Therapeutic in its Bioenergetics Restoration Franchise. Retrieved April 5, 2025, from https://www.businesswire.com/news/home/20250403945637/en/Pretzel-Therapeutics-Initiates-Phase-1-Clinical-Study-Evaluating-PX578-Lead-Therapeutic-in-its-Bioenergetics-Restoration-Franchise[8] Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation. Retrieved April 5, 2025, from https://ir.arvinas.com/news-releases/news-release-details/arvinas-presents-first-human-data-investigational-oral-protac[9] Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025. Retrieved April 5, 2025, from https://www.roche.com/media/releases/med-cor-2025-04-03[10] Jabez Biosciences, Inc. Announces First Patient Dosed in Phase 1 Oncology Clinical Study of JBZ-001. Retrieved April 5, 2025, from https://www.jabezbio.com/2025/04/03/jabez-biosciences-inc-announces-first-patient-dosed-in-phase-1-oncology-clinical-study-of-jbz-001/免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新